Medplus Health Services Limited
₹579.80-₹18.45 (-3.1%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹10,126 Cr
- P/E
- 193.0x
- EV / EBITDA
- 260.9x
- Revenue
- ₹713 Cr
- Net margin
- 1.9%
- ROCE
- 2.5%
Price chart
Technical chartScreen technicals →-23.3% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -11.4%
- 3M
- -18.9%
- 6M
- -33.4%
- 1Y
- -23.3%
- 5Y
- -46.1%
52-week range
Day change -₹18.45 (-3.1%) from ₹598 to ₹580 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in MEDPLUS, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Strong 5-year revenue CAGR of 50.2%
Concerns1
- Low return on equity of 0.8%
Rule-based from financial data. Not advice.
About the company
MedPlus Health Services Limited engages in the retail trading of medicines and general items in India.
Read moreShow less
MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It manufactures and trades in pharmaceutical and wellness products, such as prescription medicines, over-the-counter drugs, vitamins, medical devices, and diagnostic test kits; and fast-moving consumer goods (FMCG), including personal and home care products like toiletries, baby care items, soaps, detergents, and sanitizers. The company also engages in wholesale cash and carry; provision of diagnostic, pathological, and laboratory testing services, as well as contract manufacturing of private-label pharmaceuticals, wellness products, and FMCG goods; and operates diagnostic centres. It distributes its products through retail and online channels. The company was incorporated in 2006 and is based in Hyderabad, India.
- Sector
- Consumer Discretionary
- Shares outstanding
- 12.0 Cr shares
- ISIN
- INE804L01022
- BSE code
- 543427
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹10,126 Cr
- P/E
- 193.0x
- P/B
- 8.0x
- EV / EBITDA
- 260.9x
- EV / Sales
- 21.8x
- P/S
- 21.7x
- Earnings yield
- 0.5%
- 52-week high
- ₹954.65
- 52-week low
- ₹579.80
Profitability
- Operating margin
- 6.9%
- Net margin
- 1.9%
- EBITDA margin
- 8.4%
- ROE
- 0.8%
- ROCE
- 2.5%
- ROA
- 0.7%
- Dividend payout
- 0.0%
- Tax rate
- -36.0%
- Other income, % of PBT
- 100.0%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹713 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 52.7%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 50.2%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹39.0 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 34.5%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 344.4%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹8.00 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -27.3%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹2.00 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 3.0%
Solvency and efficiency
- Current ratio
- 33.91
- Debt / Equity
- 0.07
- Debt / Assets
- 0.07
- Debt / EBITDA
- 2.28
- Interest coverage
- 4.00
- Financial leverage
- 1.10
- CFO / Net profit
- 0.89
- Cash / Market cap
- 1.9%
- Cash per share
- ₹16.32
- Asset turnover
- 0.36
- Fixed asset turnover
- 2.43
- Capital intensity
- 0.41
- Debtor days
- 54 days
- Inventory turnover
- 24.33
- Cash conversion cycle
- 50 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹6 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹635 Cr |
| Sales | Operating profit | ₹78 Cr |
| Operating profit | Interest | ₹9 Cr |
| Operating profit | Depreciation | ₹27 Cr |
| Operating profit | Profit before tax | ₹42 Cr |
| Other income | Profit before tax | ₹9 Cr |
| Profit before tax | Tax and other | ₹11 Cr |
| Profit before tax | Net profit | ₹40 Cr |
Revenue and net profit
Revenue grew 52.7% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹68 Cr | -₹9 Cr |
| FY2022 | ₹146 Cr | ₹6 Cr |
| FY2023 | ₹214 Cr | ₹6 Cr |
| FY2024 | ₹467 Cr | ₹9 Cr |
| FY2025 | ₹713 Cr | ₹40 Cr |
Cash flows
FY2025: ₹47.0 Cr from operations, ₹8.00 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | -₹6 Cr | -₹21 Cr |
| FY2022 | -₹18 Cr | -₹654 Cr |
| FY2023 | ₹11 Cr | ₹43 Cr |
| FY2024 | ₹8 Cr | -₹16 Cr |
| FY2025 | ₹47 Cr | ₹8 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹713 Cr+52.7%1Y
- Net profit
- ₹40 Cr+344.4%1Y
- Cash from operations
- ₹47 Cr
- Free cash flow
- ₹8 Cr
- Revenue CAGR, 5Y
- 50.2%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹713 Cr | ₹78 Cr | — | ₹40 Cr | ₹47 Cr | ₹8 Cr | 3.2% | +52.7% | +344.4% |
Monthly returns
Month-by-month returns of MEDPLUS across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹1,399 Cr |
| Equity capital | ₹24 Cr |
| Reserves | ₹1,216 Cr |
| Borrowings | ₹95 Cr |
| Other liabilities | ₹65 Cr |
| Assets | ₹1,399 Cr |
| Fixed assets | ₹184 Cr |
| Capital work in progress | ₹1 Cr |
| Investments | ₹928 Cr |
| Other assets | ₹286 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
MEDPLUS trades at 193.0x earnings against a peer median of 55.4x (a 248% premium).
Not shown (no positive earnings and no EV / Sales): Aditya Birla Fashion and Retail Limited.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Medplus Health Services LimitedMEDPLUSthis companyP/E ↑ premium | ₹10,126 Cr | 193.0x | 8.0x | 0.8% | 260.9x |
| Cello World LimitedCELLO | ₹11,097 Cr | 113.0x | 7.4x | 8.7% | 118.0x |
| Eureka Forbes LimitedEUREKAFORB | ₹10,988 Cr | 59.7x | 2.5x | 2.2% | 59.0x |
| Safari Industries (India) Ltd.SAFARI | ₹10,398 Cr | 79.1x | 10.8x | 19.3% | 40.9x |
| Whirlpool of India LtdWHIRLPOOL | ₹10,267 Cr | 35.6x | 2.9x | 5.2% | 21.9x |
| Le Travenues Technology LimitedIXIGO | ₹9,867 Cr | 143.0x | 12.8x | 12.6% | 182.6x |
| Relaxo Footwears Ltd.RELAXO | ₹9,846 Cr | 56.5x | 4.7x | 10.0% | 22.4x |
| Honasa Consumer LimitedHONASA | ₹9,437 Cr | 75.8x | 7.5x | 10.8% | 49.7x |
| Aditya Birla Fashion and Retail LimitedABFRL | ₹8,940 Cr | — | 1.1x | -5.5% | 18.6x |
| Peer median | — | 55.4x | 6.3x | 11.8% | 36.3x |
Year-to-date ROI
MEDPLUS since 1 January, against earlier years.
Historical volatility
MEDPLUS's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | -13.0% |
| FY2022 | 2.0% |
| FY2023 | 3.0% |
| FY2024 | 7.0% |
| FY2025 | 11.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹713 Cr |
| Costs | |
| Interest | ₹9 Cr |
| Expenses | ₹635 Cr |
| Operating profitOperating Profit | ₹78 Cr |
| Other income and charges | |
| Profit before tax | ₹51 Cr |
| Tax | |
| Net profitNet Profit | ₹40 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹1,399 Cr |
| Equity capitalEquity Capital | ₹24 Cr |
| Reserves | ₹1,216 Cr |
| Borrowings | ₹95 Cr |
| Other liabilitiesOther Liabilities | ₹65 Cr |
| AssetsTotal Assets | ₹1,399 Cr |
| Fixed assetsFixed Assets | ₹184 Cr |
| Capital work in progressCWIP | ₹1 Cr |
| Investments | ₹928 Cr |
| Other assetsOther Assets | ₹286 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹47 Cr |
| Investing cash flowCash from Investing Activity | -₹39 Cr |
| Financing cash flowCash from Financing Activity | -₹10 Cr |
| Change in cashNet Cash Flow | -₹2 Cr |
Learn while you research
Academy chapters picked for Medplus Health Services Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 193.0, learn when high multiples are justified.6 min read
- 04 Growth Investing53% revenue growth is in the top tier, learn how to value growth.7 min read
- 05 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 06 Cyclical vs Defensive StocksConsumer staples behave defensively across the business cycle.6 min read